Milan, 3 mar. (Adnkronos Health) — Tomorrow, March 4, we celebrate the World Day to fight the human Papillomavirus HPV, the first cause of cervical cancer. On the occasion of the HPV Day, Lilt, the Italian League for the fight against cancer, in collaboration with the National Cancer Institute-Int of Milan, announces the launch of a national clinical study with co-test for the prevention of cervical cancer.The leader of the project, supported by 5xmille funds, is Lilt Milano Monza Brianza which, in collaboration with 5 other provincial Lilt (Padua, Genoa, Cagliari, Catanzaro and Syracuse), will enlist 2 thousand women aged between 18 and 60 years. Participants are offered a liquid-phase Pap test associated with HPV mRNA smear, a diagnostic mix that promises «maximum sensitivity and specificity in the early detection of cervical lesions.»
The expected duration of the study is 36 months, including final publication, with a recruitment period of 6 months. The biological samples in liquid phase, collected in Lilt clinics, will converge in the laboratory of Pathological Anatomy 1 of the Irccs Int Foundation where they will be processed through two innovative platforms, made available thanks to a national Lilt call.
Two objectives of the trial, explains a message: «To provide an innovative approach in the screening of cervical cancer through two integrated methods, morphological and molecular, with the increase of sensitivity in the identification of women carriers of high-grade lesions and the specificity of women who must undergo colposcopy; use the test to identify categories of patients at high risk of developing high-grade disease, to undergo accelerated treatment and control plans.»
«Cancer prevention becomes predictive thanks to a biomarker like the mRNA test that helps us identify women most at risk.After senology, in Lilt we take a step forward towards the future also in the gynecological field», says Marco Alloisio, president of Lilt Milano Monza Brianza. «The study of HPV tumor diseases becomes easier, faster and more effective, allowing us to associate the reading of the Pap-test with the most modern methods of molecular investigation», says Massimo Milione, director of the Complex Structure Pathological Anatomy 1 of the Int.
In the clinics of the Lilt Milano Monza Brianza — it is emphasized in the note — the Pap-test in liquid phase replaces the traditional Pap-test. It will thus always be possible to carry out the Hpv mRNA test as a check following an abnormal Pap test, without repeating the sampling.
The liquid phase Pap test is performed like the traditional one, but the material taken is not simply swiped on a slide, but introduced into a vial containing a solution that fixes it and allows it to be stored longer, keeping unchanged a greater number of information to be analyzed.
Access to the site is restricted and reserved for healthcare professionals
You have reached the maximum number of visits